M K Proteins

What does M K Proteins do?

M K Proteins Ltd is a micro-cap company in the edible oil industry, incorporated in 2012 and converted to a public company in 2017, with recent quarterly net sales of 137 Cr and a net profit of 3 Cr as of March 2025. Key financial metrics include a market cap of Rs 266 Cr, P/E of 31.00, and a debt-equity ratio of 0.56.

Overview:<BR>M K Proteins Ltd operates in the edible oil industry and is categorized as a micro-cap company.<BR><BR>History:<BR>M K Proteins Ltd was incorporated in 2012 as "MK Proteins Private Limited" and later converted to a public limited company in 2017. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 137 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 3 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 266 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 31.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.56 <BR>Return on Equity: 12.09% <BR>Price to Book: 3.77 <BR><BR>Contact Details:<BR>Address: Naraingarh Road, Village Garnala Ambala Haryana : 134003 <BR>Tel: 91-171-2679157/2679358 <BR>Email: info@mkproteins.in <BR>Website: http://www.mkproteins.in

Who are in the management team of M K Proteins?

As of March 2022, the management team of M K Proteins includes Vinod Kumar (Chairman & Managing Director), Raj Kumar (Whole-time Director), and several directors and independent directors. Vinod Kumar and Raj Kumar each receive a remuneration of Rs. 6.0 lacs, while Company Secretary Prerna Mehta earns Rs. 2.04 lacs.

As of March 2022, the management team of M K Proteins includes:<BR><BR>1. Vinod Kumar - Chairman & Managing Director<BR>2. Raj Kumar - Whole-time Director<BR>3. Parvind Kumar - Director<BR>4. Pramod Kumar - Director<BR>5. Chatter Singh - Independent Director<BR>6. Raman Kumar Sah - Independent Director<BR>7. Abhay Kumar - Independent Director<BR>8. Dinesh Singh Malik - Independent Director<BR>9. Laxmi Mandal - Independent Director<BR>10. Prerna Mehta - Company Secretary & Compliance Officer<BR><BR>Vinod Kumar and Raj Kumar receive a remuneration of Rs. 6.0 lacs each, while Prerna Mehta earns Rs. 2.04 lacs. The other directors do not have any remuneration listed.

What is the bonus history of the M K Proteins?

M K Proteins has a history of issuing bonuses, with the latest being a 2:1 bonus announced for March 15, 2024, following another 2:1 bonus on February 3, 2023. This demonstrates the company's commitment to rewarding its shareholders.

M K Proteins has a history of issuing bonuses, with the most recent being a 2:1 bonus issue announced for March 15, 2024. Prior to that, the company also issued a 2:1 bonus on February 3, 2023. This consistent approach to bonus issues reflects the company's strategy to reward its shareholders. If you have any more questions about M K Proteins or need further details, feel free to ask!

Has M K Proteins declared dividend?

No Dividend History Available

What is the technical trend for M K Proteins?

As of May 12, 2025, M K Proteins shows a mildly bearish trend overall, with mixed signals from various indicators, including a mildly bullish weekly MACD and Bollinger Bands, but daily moving averages indicating caution.

As of 12 May 2025, the technical trend for M K Proteins has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the daily moving averages indicate a mildly bearish stance. The Bollinger Bands on the weekly chart are also mildly bullish, contrasting with the monthly view which is bearish. The KST shows a mildly bullish trend on the weekly timeframe, and Dow Theory supports a mildly bullish outlook as well. However, the overall sentiment remains cautious due to the daily moving averages and the lack of strong signals from the RSI and OBV. The current technical stance is mildly bearish, reflecting mixed signals across different indicators.

Who are the peers of the M K Proteins?

M K Proteins' peers include Evexia Lifecare, Gokul Refoils, Ajanta Soya, Vijay Solvex, Raj Oil Mills, Prime Industries, Ambo Agritec, and Ramdevbaba Sol. M K Proteins has a good capital structure and management risk but a low 1-year return of -36.96%, significantly lower than Ajanta Soya's 20.80%.

Peers: The peers of M K Proteins are Evexia Lifecare, Gokul Refoils, Ajanta Soya, Vijay Solvex, Raj Oil Mills, Prime Industries, Ambo Agritec, and Ramdevbaba Sol.<BR><BR>Quality Snapshot: Excellent capital structure is observed at Ajanta Soya, while Good capital structure is found at M K Proteins and Vijay Solvex, and the rest have Below Average or do not qualify. Average management risk is observed at Evexia Lifecare, Gokul Refoils, Prime Industries, Ambo Agritec, Ramdevbaba Sol, and the rest, while Good management risk is noted at M K Proteins. Below Average growth is found at Evexia Lifecare, Gokul Refoils, Vijay Solvex, Prime Industries, and the rest, while Average growth is observed at Ambo Agritec and Ramdevbaba Sol.<BR><BR>Return Snapshot: Ajanta Soya has the highest 1-year return at 20.80%, while M K Proteins has the lowest at -36.96%. M K Proteins' return is significantly lower than Ajanta Soya's. Additionally, the six-month return is negative for Evexia Lifecare, Gokul Refoils, Vijay Solvex, Prime Industries, and Ramdevbaba Sol.

Who are the top shareholders of the M K Proteins?

The top shareholders of M K Proteins are primarily promoters, with Pragun Garg holding the largest individual stake at 6.33%. Individual investors collectively own 21.6% of the shares, and there are no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of M K Proteins primarily consist of the promoters, with Pragun Garg holding the highest individual stake at 6.33%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, individual investors collectively hold 21.6% of the company's shares.

How big is M K Proteins?

As of 24th July, M K Proteins Ltd has a market capitalization of 274.00 Cr, with recent net sales of 267.70 Cr and a net profit of 8.40 Cr. Shareholder's funds are 61.08 Cr and total assets amount to 95.87 Cr as of March 2024.

As of 24th July, M K Proteins Ltd has a market capitalization of 274.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, M K Proteins reported Net Sales of 267.70 Cr and a Net Profit of 8.40 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 61.08 Cr and Total Assets of 95.87 Cr.

Are M K Proteins latest results good or bad?

M K Proteins' latest results are strong, with net sales growing 100.51% year-on-year to Rs 114.95 crore, and significant increases in Profit Before Tax and Profit After Tax by 41.02% and 41.5%, respectively, indicating robust financial performance.

M K Proteins has reported strong financial results for the quarter ending June 2025, indicating a positive performance. The company achieved net sales of Rs 114.95 crore, which is an impressive year-on-year growth of 100.51%. This significant increase suggests a robust sales trend.<BR><BR>Additionally, the Profit Before Tax (PBT) rose to Rs 4.71 crore, marking a 41.02% increase compared to the same quarter last year. The Profit After Tax (PAT) also saw a healthy rise of 41.5%, reaching Rs 3.51 crore. <BR><BR>Furthermore, the operating profit (PBDIT) reached its highest level in the last five quarters at Rs 5.51 crore, indicating improved operational efficiency. The Earnings per Share (EPS) also hit a five-quarter high at Rs 0.09, reflecting enhanced profitability for shareholders.<BR><BR>Overall, M K Proteins has demonstrated strong growth across multiple financial metrics, making the latest results quite favorable.

Is M K Proteins overvalued or undervalued?

As of November 19, 2025, M K Proteins is considered very attractive and undervalued, with a PE ratio of 28.91, an EV to EBITDA of 18.57, and a ROCE of 17.66%, making it a compelling investment opportunity despite a year-to-date return of -20.34%.

As of 19 November 2025, the valuation grade for M K Proteins has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE ratio of 28.91, an EV to EBITDA of 18.57, and a ROCE of 17.66%. <BR><BR>In comparison to its peers, M K Proteins has a significantly lower PE ratio than Manorama Industries, which stands at 45.44, and a more favorable EV to EBITDA ratio than CIAN Agro, which is at 16.34. Despite recent underperformance, with a year-to-date return of -20.34% compared to the Sensex's 9.02%, the strong valuation metrics suggest that M K Proteins presents a compelling investment opportunity.

How has been the historical performance of M K Proteins?

M K Proteins' historical performance shows fluctuating revenue, with net sales increasing to 267.71 Cr in March 2025 from 245.57 Cr in March 2024, but declining from 314.86 Cr in March 2023. Profitability decreased, with operating profit falling to 12.43 Cr and cash flow showing a negative trend, indicating challenges in profitability and cash management despite some sales growth.

Answer:<BR>The historical performance of M K Proteins shows fluctuations in key financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>M K Proteins reported net sales of 267.71 Cr in March 2025, an increase from 245.57 Cr in March 2024, but a decline from 314.86 Cr in March 2023. The total operating income followed a similar trend, reaching 267.71 Cr in March 2025 compared to 245.57 Cr in the previous year. The company's total expenditure, excluding depreciation, was 255.28 Cr in March 2025, up from 228.95 Cr in March 2024. Operating profit, excluding other income, decreased to 12.43 Cr in March 2025 from 16.62 Cr in March 2024, leading to an operating profit margin of 4.64%. Profit before tax also declined to 11.45 Cr in March 2025 from 15.47 Cr in March 2024, resulting in a profit after tax of 8.40 Cr. The company's total assets increased to 130.23 Cr in March 2025 from 95.87 Cr in March 2024, while total liabilities rose to 130.23 Cr from 95.87 Cr in the same period. Cash flow from operating activities showed a negative trend, with a cash outflow of 16.00 Cr in March 2025, contrasting with a positive inflow of 32.00 Cr in March 2024. Overall, M K Proteins experienced a mixed performance with some growth in sales but challenges in profitability and cash flow management.

Should I buy, sell or hold M K Proteins?

When is the next results date for M K Proteins Ltd?

The next results date for M K Proteins Ltd is 13 February 2026.

The next results date for M K Proteins Ltd is scheduled for 13 February 2026.

Why is M K Proteins Ltd falling/rising?

As of 07-Feb, M K Proteins Ltd's stock price is declining at 5.31, down 1.48%, with a total drop of 12.95% year-to-date, significantly underperforming the Sensex. Contributing factors include poor net sales growth, a dramatic fall in quarterly profits, and decreased liquidity, despite a low debt-to-equity ratio and reasonable return on equity.

As of 07-Feb, M K Proteins Ltd is experiencing a decline in its stock price, currently at 5.31, which reflects a change of -0.08 or -1.48%. The stock has been on a downward trend, having fallen consecutively for the last two days, resulting in a total decline of -2.39% during this period. Over the past week, the stock has decreased by -3.28%, while the benchmark Sensex has risen by +1.59%, indicating underperformance relative to the market.<BR><BR>The stock's performance over the past month shows a significant drop of -11.65%, contrasting with a slight decline of -1.74% in the Sensex. Year-to-date, M K Proteins Ltd has seen a decrease of -12.95%, while the Sensex has only fallen by -1.92%. Over the past year, the stock has generated a return of -30.50%, which is considerably worse than the +7.07% return of the Sensex.<BR><BR>Several factors contribute to this decline. The company's net sales growth has been poor, averaging only 6.60% annually over the last five years, and its profits have decreased by -25% in the same timeframe. The latest quarterly profit after tax (PAT) has fallen dramatically by -56.9%, and the operating cash flow is at its lowest, recorded at Rs -16.13 crore. Additionally, the stock's liquidity has decreased, with delivery volume dropping by -67.4% compared to the five-day average.<BR><BR>Despite having a low debt-to-equity ratio and an attractive valuation with a return on equity (ROE) of 11.4, the overall performance of M K Proteins Ltd has been below par in both the long term and near term. This combination of declining profits, poor sales growth, and underperformance against benchmarks has led to the current fall in stock price.

Which are the latest news on M K Proteins?